Abstract:Germline variants occurring in BRCA1 and BRCA2 give rise to hereditary breast and ovarian cancer (HBOC) syndrome, predisposing to breast, ovarian, fallopian tube, and peritoneal cancers marked by elevated incidences of genomic aberrations that correspond to poor prognoses. These genes are in fact involved in genetic integrity, particularly in the process of homologous recombination (HR) DNA repair, a high-fidelity repair system for mending DNA double-strand breaks. In addition to its implication in HBOC pathogenesis, the impairment of HR has become a prime target for therapeutic intervention utilizing poly (ADP-ribose) polymerase (PARP) inhibitors. In the present review, we introduce the molecular roles of HR orchestrated by BRCA1 and BRCA2 within the framework of sensitivity to PARP inhibitors. We examine the genetic architecture underneath breast and ovarian cancer ranging from high- and mid- to low-penetrant predisposing genes and taking into account both germline and somatic variations. Finally, we consider higher levels of complexity of the genomic landscape such as polygenic risk scores and other approaches aiming to optimize therapeutic and preventive strategies for breast and ovarian cancer.

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the genetic basis of breast cancer and ovarian cancer, especially by analyzing the data and lessons learned from genetic susceptibility tests in the past 30 years. Specifically, the paper focuses on the following aspects: 1. **The role of BRCA1 and BRCA2 genes**: It explores the molecular mechanisms of BRCA1 and BRCA2 genes in homologous recombination (HR) repair, and how the dysfunction of these genes leads to the occurrence of breast cancer and ovarian cancer. In addition, it also discusses the potential of HR dysfunction as a treatment target, especially the treatment strategy using poly (ADP - ribose) polymerase (PARP) inhibitors. 2. **Types of genetic variations and their impacts**: It describes in detail different types of pathogenic variations in BRCA1 and BRCA2 genes, including truncating mutations, missense mutations, copy number variations (CNVs), etc., and analyzes the impacts of these variations on disease risk. 3. **Genotype - phenotype correlations**: It explores the relationships between specific variations in BRCA1 and BRCA2 genes and clinical phenotypes, including the specific associations between different variation sites and the risks of breast cancer and ovarian cancer. 4. **Other high - penetrance genes**: Besides BRCA1 and BRCA2, the paper also discusses other high - penetrance genes related to the risks of breast cancer and ovarian cancer, such as ATM, CHEK2, PALB2, PTEN and TP53, etc., and provides detailed data on the variations of these genes and cancer risks. 5. **The application of multigene testing**: It introduces the application of multigene testing in the risk assessment of breast cancer and ovarian cancer, and how this testing method improves the identification and management of high - risk individuals. 6. **Optimization of prevention and treatment strategies**: Finally, the paper proposes prevention and treatment strategies based on genetic information, aiming to improve the prognosis of breast cancer and ovarian cancer patients through more accurate risk assessment and personalized treatment regimens. In summary, the main purpose of this paper is to comprehensively summarize the genetic basis of breast cancer and ovarian cancer by reviewing the research achievements in the past 30 years, and to propose the directions for future research and clinical applications.

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing

Hereditary breast and ovarian cancer: from genes to molecular targeted therapies

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature

BRCA mutations in the manifestation and treatment of ovarian cancer.

Breast cancer (BRCA) gene testing in ovarian cancer.

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?

Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges

Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries

Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in BRCA and in Other Susceptibility Genes

Disparities in Genetic Management of Breast and Ovarian Cancer Patients

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study

Supplementary Tables S1-S4 from the BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms

Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol

A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer